2seventy bio Q3 Adj. EPS $(1.00) Misses $(0.97) Estimate, Sales $12.03M Miss $35.18M Estimate
Portfolio Pulse from Benzinga Newsdesk
2seventy bio (NASDAQ:TSVT) reported a Q3 adjusted EPS of $(1.00), missing the $(0.97) estimate, and sales of $12.03M, falling short of the $35.18M estimate. This represents a 43.18% increase in EPS losses and a 10.25% decrease in sales from the same period last year.
November 14, 2023 | 12:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
2seventy bio's Q3 earnings report showed a greater loss per share and lower sales than expected, indicating potential challenges ahead.
Missing both EPS and sales estimates can be seen as a negative indicator of a company's financial health and often leads to a negative short-term reaction in the stock market. The reported increase in EPS losses and decrease in sales from the previous year further underscore the company's challenges.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100